Analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report $0.14 EPS on January, 24.They anticipate $0.01 EPS change or 6.67% from last quarter’s $0.15 EPS. VIVO’s profit would be $5.92 million giving it 27.32 P/E if the $0.14 EPS is correct. After having $0.15 EPS previously, Meridian Bioscience, Inc.’s analysts see -6.67% EPS growth. The stock decreased 0.97% or $0.15 during the last trading session, reaching $15.3. About 219,396 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since January 14, 2017 and is downtrending. It has underperformed by 43.54% the S&P500.
Colony Group Llc increased Expedia Inc Com (EXPE) stake by 30.4% reported in 2017Q3 SEC filing. Colony Group Llc acquired 7,993 shares as Expedia Inc Com (EXPE)’s stock rose 18.57%. The Colony Group Llc holds 34,287 shares with $4.94M value, up from 26,294 last quarter. Expedia Inc Com now has $20.18B valuation. The stock increased 2.28% or $2.95 during the last trading session, reaching $132.36. About 2.25 million shares traded. Expedia, Inc. (NASDAQ:EXPE) has risen 30.43% since January 14, 2017 and is uptrending. It has outperformed by 13.73% the S&P500.
Colony Group Llc decreased Sector Spdr Tr Shs Ben Int Industrial (XLI) stake by 5,117 shares to 5,845 valued at $415,000 in 2017Q3. It also reduced Amgen Inc (NASDAQ:AMGN) stake by 2,385 shares and now owns 100,024 shares. Merck & Co Inc (NYSE:MRK) was reduced too.
Among 36 analysts covering Expedia Inc. (NASDAQ:EXPE), 27 have Buy rating, 0 Sell and 9 Hold. Therefore 75% are positive. Expedia Inc. has $190 highest and $27 lowest target. $150.25’s average target is 13.52% above currents $132.36 stock price. Expedia Inc. had 106 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 25 by Wells Fargo. The rating was maintained by Deutsche Bank with “Buy” on Friday, July 31. On Friday, October 30 the stock rating was maintained by RBC Capital Markets with “Outperform”. Stifel Nicolaus maintained it with “Hold” rating and $160.0 target in Wednesday, August 30 report. UBS maintained the stock with “Buy” rating in Friday, October 27 report. The stock has “Buy” rating by Benchmark on Monday, October 24. The stock of Expedia, Inc. (NASDAQ:EXPE) has “Buy” rating given on Wednesday, January 10 by Morgan Stanley. The firm has “Sell” rating given on Monday, February 22 by Stifel Nicolaus. The stock of Expedia, Inc. (NASDAQ:EXPE) earned “Sector Weight” rating by Pacific Crest on Thursday, March 31. The firm earned “Buy” rating on Wednesday, October 11 by RBC Capital Markets.
Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.14, from 1.29 in 2017Q2. It improved, as 42 investors sold EXPE shares while 152 reduced holdings. 84 funds opened positions while 193 raised stakes. 124.65 million shares or 0.14% more from 124.48 million shares in 2017Q2 were reported. Ardsley Advisory Prtnrs has invested 0.89% in Expedia, Inc. (NASDAQ:EXPE). Baltimore has invested 0.49% in Expedia, Inc. (NASDAQ:EXPE). Piedmont Investment Advsrs Lc reported 0.02% in Expedia, Inc. (NASDAQ:EXPE). Ig Investment Limited stated it has 113,700 shares. Menta Ltd Liability accumulated 0.1% or 4,942 shares. Lpl Financial Ltd Llc reported 0.01% of its portfolio in Expedia, Inc. (NASDAQ:EXPE). Moreover, Assetmark has 0% invested in Expedia, Inc. (NASDAQ:EXPE). Deutsche Commercial Bank Ag holds 376,458 shares or 0.04% of its portfolio. Mason Street Advisors Ltd Co, Wisconsin-based fund reported 16,960 shares. Mirae Asset Glob Invs Ltd invested in 0.02% or 9,239 shares. Light Street Cap Management Lc holds 3.53% or 300,000 shares. Linscomb And Williams owns 1,997 shares. Invesco stated it has 1.63 million shares. Brandywine Managers Lc, a Delaware-based fund reported 4,535 shares. Clarivest Asset Mngmt Limited Liability Co accumulated 7 shares.
Investors sentiment increased to 1.37 in 2017 Q3. Its up 0.02, from 1.35 in 2017Q2. It increased, as 12 investors sold Meridian Bioscience, Inc. shares while 42 reduced holdings. 24 funds opened positions while 50 raised stakes. 36.26 million shares or 2.14% more from 35.50 million shares in 2017Q2 were reported. Glenmede Tru Company Na invested in 0% or 1,410 shares. Ameriprise Financial Inc reported 263,674 shares. Bartlett & Limited Liability Company accumulated 5,739 shares or 0% of the stock. Jpmorgan Chase & Com stated it has 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Tudor Inv Et Al, Connecticut-based fund reported 49,584 shares. Deutsche Natl Bank Ag holds 0% or 196,995 shares. Brown Cap Lc has invested 0.96% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Lapides Asset Ltd Liability Company has 0.06% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 21,000 shares. Gotham Asset Lc owns 196,214 shares. Envestnet Asset Management Inc owns 231 shares. Intll Group, New York-based fund reported 33,051 shares. Sector Pension Board accumulated 26,771 shares. Mondrian Partners Ltd has invested 0.06% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Prudential Public Ltd Co, Illinois-based fund reported 923,400 shares. Bank & Trust Of Ny Mellon owns 871,560 shares for 0% of their portfolio.
Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $647.31 million. The firm operates through Diagnostics and Life Science divisions. It has a 30 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.
Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 10 analyst reports since July 28, 2015 according to SRatingsIntel. Hilliard Lyons upgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) on Monday, March 28 to “Buy” rating. As per Thursday, September 10, the company rating was maintained by Canaccord Genuity. The rating was maintained by Piper Jaffray with “Sell” on Thursday, September 21. The stock has “Sell” rating by Piper Jaffray on Thursday, July 27. The rating was maintained by Piper Jaffray with “Sell” on Thursday, October 19. The stock has “Hold” rating by Robert W. Baird on Thursday, October 19. Hilliard Lyons downgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) on Monday, March 21 to “Neutral” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.